Affirma Capital to invest in Chinese lozenges manufacturer PE firm to acquire 25.6% stake in Golden Throat Holdings
Translated by Kim So-in 공개 2021-09-07 08:11:05
이 기사는 2021년 09월 07일 08:07 thebell 에 표출된 기사입니다.
Singapore-headquartered private equity (PE) firm Affirma Capital will acquire a controlling stake in Golden Throat Holdings, a leading manufacturer of lozenges in China.Affirma Capital will acquire a 25.6% stake in the Hong Kong-listed company for HK$530 million (about 80 billion won), or HK$2.80 apiece, a 26% premium to Golden Throat's last closing price, accoding to industry sources on Friday. Affirma Capital’s Korean fund and a global fund will finance about 50% of the acquisition cost, respectively.
Founded in 1956, Golden Throat is the largest lozenges manufacturer in China, with a market share of 25%.
The PE firm plans to withdraw the listing of the company from the Hong Kong Stock Exchange and list it on the Chinese stock market to increase its corporate value.
Affirma Capital is preparing to get approval from the Hong Kong Stock Exchange and Hong Kong Securities and Futures Commission and plans to submit its Scheme Document around September 21. The transaction is likely to be completed around November.
Affirma Capital's fifth Korean Fund, which will finance the deal, initially closed at 450 billion won at the end of last year, with final closing expected in October. It has made three investments since its first closing.
Affirma Capital has been spun out of Standard Chartered Bank after a complex three-year process involving over 50 investments across six regions. The firm not only uses each region’s individual funds for investment, backed by local institutional investors, but also capitalizes on a global pool of capital by using its Global Fund series, formed mainly for principal investments. (Reporting by Hee-yeon Han)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 한양, 만기도래 회사채 '사모채'로 차환한다
- 동인기연, 'GS 출신' 30년 베테랑 전호철 상무 영입 '성장 방점'
- 에스트래픽, 적자 '일시적 현상'... 2분기 수익개선 기대
- [Company Watch]'자회사 회생신청' 투비소프트, 성과 없는 신사업
- '크라우드 펀딩' 와디즈, '테슬라 요건' 상장 추진
- [우리투자증권의 부활]그룹 황태자로 키울까…우리지주 '추가출자' 불가피
- [금융지주 CEO 책임경영 진단]진옥동 회장, 글로벌·자본시장 '톱 레벨' 기반 구축 경과는
- [라인야후 탈네이버 논란]주인 바뀐 라인넥스트, 블록체인 사업 추진 '오히려 좋아'
- [보험사 지급여력 돋보기]DB손보, 줄어든 '보험위험'에 버퍼 확보
- AI 외치는 삼성, 자신감·위기감 '공존'